Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 14 Similar Profiles
Pulmonary Hypertension
Medicine & Life Sciences
Heart Transplantation
Medicine & Life Sciences
Heart-Assist Devices
Medicine & Life Sciences
Heart Failure
Medicine & Life Sciences
Transplantation
Medicine & Life Sciences
Tissue Donors
Medicine & Life Sciences
Transplants
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2012 2022
Pulmonary Hypertension
Multicenter Studies
Safety
treprostinil
Heart Failure
Placebos
Safety
Pitch Heart Failure Study: Phosphodiesterase Type 5 Inhi
New England Research Institutes
3/31/14 → 12/31/14
Project: Research project
Type 5 Cyclic Nucleotide Phosphodiesterases
Heart Failure
Tadalafil
Pulmonary Hypertension
Nitric Oxide
Placebos
Safety
Therapeutics
Research Output 1980 2019
1
Citation
(Scopus)
Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease
Prins, K. W., Rose, L., Archer, S. L., Pritzker, M. R., Weir, E. K., Olson, M. D. & Thenappan, T., Jan 1 2019, In : Journal of the American Heart Association. 8, 2, e011464.Research output: Contribution to journal › Article
Right Ventricular Dysfunction
Pulmonary Hypertension
Lung Diseases
Heart Ventricles
Chronic Disease
3
Citations
(Scopus)
Repurposing medications for treatment of pulmonary arterial hypertension: What’s old is new again
Prins, K. W., Thenappan, T., Weir, E. K., Kalra, R., Pritzker, M. & Archer, S. L., Jan 1 2019, In : Journal of the American Heart Association. 8, 1, e011343.Research output: Contribution to journal › Review article
Right Ventricular Function
Pulmonary Hypertension
Pulmonary Artery
3
Citations
(Scopus)
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide
Rose, L., Prins, K. W., Archer, S. L., Pritzker, M. R., Weir, E. K., Misialek, J. R. & Thenappan, T., Feb 2019, In : Journal of Heart and Lung Transplantation. 38, 2, p. 145-155 11 p.Research output: Contribution to journal › Article
Lung Volume Measurements
Carbon Monoxide
Pulmonary Hypertension
Lung Diseases
Chronic Disease
Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Holthaus, N., Prins, K. W., Rose, L., Prisco, S., Pritzker, M. & Thenappan, T., Jul 1 2019, In : Pulmonary Circulation. 9, 3Research output: Contribution to journal › Article
Open Access
Epoprostenol
Pulmonary Hypertension
Epoprostenol Receptors
selexipag
Vascular Diseases
5
Citations
(Scopus)
Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension
Prins, K. W., Rose, L., Archer, S. L., Pritzker, M. R., Weir, E. K., Kazmirczak, F., Misialek, J. R. & Thenappan, T., Jun 1 2018, In : American journal of respiratory and critical care medicine. 197, 11, p. 1496-1499 4 p.Research output: Contribution to journal › Letter
Open Access
Right Ventricular Dysfunction
Pulmonary Hypertension